从畴前、刻下到将来，看华山神内巨匠空说念的疾病修饰疗法~

帕金森病（PD）是一种常见的中老年神经系统退行性疾病，减速或松懈PD神经退行性变的程度是帕金森病调整范围的艰巨。疾病修饰疗法（DMT）是一种更正疾病当然病程的骚扰看成，不错影响神经元变性的运转触发要素，并促使神经元代偿反馈或减少病理传播和弘扬。

那么，哪些药物不错用于PD的DMT，刻下PD的DMT有何弘扬，将来又濒临哪些挑战？今天这份来自华山神内巨匠的精彩西宾，全球一王人望望！

PD修饰疗法的畴前

畴前的二三十年中，PD的药物调整和手术调整都得回了长足的很是。诚然PD的DMT故步自命，但国表里学者进行了积极的探索，其中不乏有蹙迫的计划恶果。

DATATOP计划

DATATOP计划将800例未经调整的早期PD患者速即分为司来吉兰+维生素E调整组与安危剂组，将需要进行左旋多巴调整的本事设定为非常事件与主要结局研讨。

搁置发现，司来吉兰+维生素E调整不错延长左旋多巴使用9个月。但计划搁置只可讲解司来吉兰不错推迟了左旋多巴的使用本事，而左旋多巴的使用本事可能受到多种要素影响，因此DATATOP计划不可证据司来吉兰具有疾病修饰作用。

状元公大乐透第2023065期前区奖号除5余数分析：

热号分析：最近十周星期六前区热号出现24个，每期平均开出2.4个，热号与理论个数基本相当，上周星期六热号开出3个，热码走势非常明显，本周星期六重点关注热号出现，目前星期六热号有17个，本期预计出现3-4个，关注热号14 23 33。

ELLDOPA计划

ELLDOPA计划是为考证左旋多巴对多巴胺神经元是否有毒性而策动的，计划纳入361名早期未经调整的PD患者，速即分为4组：左旋多巴150、300、600 mg/d以及安危剂组，用药40周后洗脱2周，不雅察洗脱前后疗效变化。

搁置发现，使用左旋多巴各组的UPDRS通顺评分恶化在洗延期后仍小于安危剂组，以左旋多巴600 mg/d组通顺症状恶化最小。

ELLDOPA计划未能证据左旋多巴毒性，反而教唆早期使用左旋多巴对PD患者无不良影响。但由于该计划影像学搁置与临床计划论断相矛盾，因此，左旋多巴对多巴胺神经元是否有毒性作用概况能否修饰疾病程度尚难以下定论。

ADAGIO计划

ADAGIO计划纳入1176名未经调整的PD患者，速即分为早期调整组（禁受剂量为每天1mg或2mg的雷沙吉兰调整72周）和延长调整组（先安危剂调整36周，再每天神用1mg或2mg雷沙吉兰调整36周）。

搁置发现，1mg/d雷沙吉兰早期调整组昭彰优于延长调整组，而2mg/d雷沙吉兰可能不具有疾病修饰作用。但该计划随访3年的搁置教唆，早期调整与延长调整的UPDRS总分无权贵性互异，因此雷沙吉兰的疾病修饰作用仍不可笃定。

PD修饰疗法的近况怎么？

皇冠体育hg86a

哪些药物不错用于PD的DMT？

PD的DMT在将来将迎来哪些挑战？

机遇又在那处？

扫描下方二维码，搜索复旦大学附属华山病院神经内科王坚西宾《帕金森病的疾病修饰疗法》精彩讲座，为您呈现

可免认证48小时不雅看统统课程，

飞速来试看！

参考文件：

[1] Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 Jan 21;328(3):176-83. doi: 10.1056/NEJM199301213280305. PMID: 8417384.

[2] Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508. doi: 10.1056/NEJMoa033447. PMID: 15590952.

[3]Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268-78. doi: 10.1056/NEJMoa0809335. Erratum in: N Engl J Med. 2011 May 12;364(19):1882. PMID: 19776408.

[4]Teng JS, Ooi YY, Chye SM, Ling APK, Koh RY. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. doi: 10.2174/1871527320666210526160926. PMID: 34042040.

[5]Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. PMID: 35921451.

[6]Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054. Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17. PMID: 31211448; PMCID: PMC6771554.

[7]Volc D, Poewe W, Kutzelnigg A, Lührs P, Thun-Hohenstein C, Schneeberger A, Galabova G, Majbour N, Vaikath N, El-Agnaf O, Winter D, Mihailovska E, Mairhofer A, Schwenke C, Staffler G, Medori R. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020 Jul;19(7):591-600. doi: 10.1016/S1474-4422(20)30136-8. PMID: 32562684.

[8]Poewe W, Volc D, Seppi K, Medori R, Lührs P, Kutzelnigg A, Djamshidian A, Thun-Hohenstein C, Meissner WG, Rascol O, Schneeberger A, Staffler G; AFF011 investigators; AFF011 study investigators:; Poewe W, Seppi K, Djamshidian A, deMarzi R, Heim B, Mangesius S, Stolz R, Wachowicz K, Volc D, Thun-Hohenstein C, Riha C, Schneeberger A, Bürger V, Galabova G. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study. J Parkinsons Dis. 2021;11(3):1079-1089. doi: 10.3233/JPD-212594. PMID: 34092654; PMCID: PMC8461711.

[9]Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013 Jun;123(6):2730-6. doi: 10.1172/JCI68295. PMID: 23728174; PMCID: PMC3668846.

[10]Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. PMID: 28781108; PMCID: PMC5831666.

[11]Bu LL, Liu YQ, Shen Y, Fan Y, Yu WB, Jiang DL, Tang YL, Yang YJ, Wu P, Zuo CT, Koprich JB, Liu FT, Wu JJ, Wang J. Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy. Neurotherapeutics. 2021 Apr;18(2):962-978. doi: 10.1007/s13311-021-01018-5. Epub 2021 Mar 15. PMID: 33723752; PMCID: PMC8423983.

[12]Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704. PMID: 25401511; PMCID: PMC4399368.

[13]Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, Lu XH, Lin X, Ye DY, Wang J, Chu Y. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system. Bioorg Med Chem. 2020 Apr 1;28(7):115358. doi: 10.1016/j.bmc.2020.115358. Epub 2020 Feb 6. PMID: 32081628.

[14]Bian J, Liu YQ, He J, Lin X, Qiu CY, Yu WB, Shen Y, Zhu ZY, Ye DY, Wang J, Chu Y. Discovery of styrylaniline derivatives as novel alpha-synuclein aggregates ligands. Eur J Med Chem. 2021 Dec 15;226:113887. doi: 10.1016/j.ejmech.2021.113887. Epub 2021 Oct 2. PMID: 34624824.